Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
Konstantinopoulos, Panagiotis A
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). [electronic resource] - Gynecologic oncology 07 2018 - 9-13 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
1095-6859
10.1016/j.ygyno.2018.04.572 doi
Adenocarcinoma, Clear Cell--drug therapy
Adult
Aged
Anilides--administration & dosage
Fallopian Tube Neoplasms--drug therapy
Female
Humans
Middle Aged
Ovarian Neoplasms--drug therapy
Peritoneal Neoplasms--drug therapy
Pyridines--administration & dosage
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). [electronic resource] - Gynecologic oncology 07 2018 - 9-13 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
1095-6859
10.1016/j.ygyno.2018.04.572 doi
Adenocarcinoma, Clear Cell--drug therapy
Adult
Aged
Anilides--administration & dosage
Fallopian Tube Neoplasms--drug therapy
Female
Humans
Middle Aged
Ovarian Neoplasms--drug therapy
Peritoneal Neoplasms--drug therapy
Pyridines--administration & dosage